|
|
|
|
|
25.04.26 - 09:24
|
Here’s how Barclays shares could climb another 40% (Fool)
|
|
|
Stock markets are clouded by geopolitical threats at the moment, but Barclays' shares could be heading for a further upwards surge.
The post Here's how Barclays shares could climb another 40% appeared first on The Motley Fool UK....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
24.04.26 - 23:09
|
CORRECTING and REPLACING US Metro Bancorp Announces First Quarter 2026 Results (Business Wire)
|
|
|
GARDEN GROVE, Calif.--(BUSINESS WIRE)--Under "CONSOLIDATED FINANCIAL HIGHLIGHTS (unaudited)," the table titled "At or for the Twelve Months Ended" shoud be removed.
The updated release reads:
US METRO BANCORP ANNOUNCES FIRST QUARTER 2026 RESULTS
US Metro Bancorp (OTCQX: USMT): US Metro Bancorp (“Bancorp”) is a bank holding company, with a single subsidiary, US Metro Bank (“Bank”). On a consolidated basis, Bancorp earned $3.3 million in the first quarter of 2026, compared to $2.2 million in the fourth quarter of 2025. For the three months ending March 31, 2026, the consolidated Bancorp earned $3.3 million compared to $2.6 million for the three months ending March 31, 2025. On a year-to-date basis, Bancorp recorded an annualized return on average assets (“ROAA”) of 0.86% and an annualized return on average equity (“ROAE”) of 11.77%. With 16,738,500 shares outstanding, earnings per share (“EPS”) for the first quarter of 2026 was $0.20 compared to $0.14 in the fourth qu...
|
|
|
|
|
24.04.26 - 21:42
|
Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro′s Anticipatory Breach Claim (GlobeNewswire EN)
|
|
|
SAN DIEGO, April 24, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today announced that the Delaware Chancery Court has dismissed Tesaro's anticipatory breach of contract claim against Anaptys. The ruling agrees with Anaptys' position that it has never repudiated the Collaboration and Exclusive License Agreement (“Collaboration Agreement”) with Tesaro, a subsidiary of GSK, governing the development and commercialization of Jemperli....
|
|